Related Experiment Video
Updated: Apr 12, 2026
11:20
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
11.5K
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring
Summary
Pulmonary sarcomatoid carcinomas (SC) show frequent mutations in KRAS, EGFR, and TP53. Despite histological differences, molecular analysis reveals some homogeneity, suggesting eligibility for targeted therapies and clinical trials.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Pulmonary sarcomatoid carcinomas (SC) are aggressive lung tumors.
- SC exhibit resistance to standard chemotherapy and have a poor prognosis.
- Understanding the molecular landscape of SC is crucial for developing effective treatments.
Purpose of the Study:
- To characterize the mutational profile of pulmonary sarcomatoid carcinomas (SC).
- To identify common genetic alterations and co-mutations in SC.
- To assess intratumoral molecular homogeneity in SC.
Main Methods:
- Mass spectrometry was used for high-throughput genotyping.
- 114 surgical biopsies from 81 SC patients were analyzed.
- 214 mutations across 26 oncogenes and tumor suppressor genes were tested.
Main Results:
- A high mutation rate was observed, with 69.1% of tumors harboring at least one mutation.
- Frequent mutations included KRAS (27.2%), EGFR (22.2%), and TP53 (22.2%).
- Co-mutations were common (39.5%), and some intratumoral molecular homogeneity was detected despite histological heterogeneity.
Conclusions:
- SC tumors display a high frequency of mutations and co-mutations.
- Despite histological variability, a degree of molecular homogeneity exists within tumors.
- These findings support screening SC patients for targeted therapies and clinical trials.
